Skip to main content

Fiscal Wizard · Single-issue tearsheet

PTCT / Jun 20, 2026 Run #7168

PTCT

PTC Therapeutics, Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Composite verdict

A 93.5 / 100
Bullish setup · Trend Following 14 drivers · 4 gates blocking
  • Rate of Change
  • Chaikin Money Flow
  • Ichimoku
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 3rd of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile range
Bull 100%Evidence: High · 20 signals0% Bear
Momentum Bullish 99Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from
Asset value $-2.48Earnings power value $122.23Price $78.98

The discount is mostly unpriced earnings power: price ($78.98) sits between asset value ($-2.48) and no-growth earnings power value ($122.23).

Fundamentals Strong

86.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Inventory Turnover 0
Revenue Growth (YoY) 100
Cash Conversion Cycle 0
Asset Turnover 100
PEG 4

Technicals Bullish

100.0 / 100

Bullish setup leads (Rate of Change, Chaikin Money Flow, Ichimoku); bears gated by guards. · 43 signals shown.

Strongest
Weakest
Rate of Change 95
Chaikin Money Flow 93
Vortex Signal 90

Risk Gates

4 blocking 4 caution

4 guards active, 18 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for PTCT.